Publikace a odborné prezentace

• Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, Cordtz R, De Cock D, Dreyer L, Elkayam O, Hauge EM, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Kristianslund EK, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Strangfeld A, Verschueren P, Courvoisier DS, Finckh A.
  Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration
  Ann Rheum Dis. ; 2022 Oct;81(10):1358-1366. doi: 10.1136/annrheumdis-2022-222586. Epub 2022 Jun 15. Erratum in: Ann Rheum Dis. 2024 Jan 2;83(1):e1. PMID: 35705376; PMCID: PMC9484385.
• Pombo-Suarez M, Sanchez-Piedra C, Gómez-Reino J, Lauper K, Mongin D, Iannone F, Pavelka K, Nordström DC, Inanc N, Codreanu C, Hyrich KL, Choquette D, Strangfeld A, Leeb BF, Rotar Z, Rodrigues A, Kristianslund EK, Kvien TK, Elkayam O, Lukina G, Bergstra SA, Finckh A, Courvoisier DS.
  After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
  Ann Rheum Dis. 2023 Feb;82(2):175-181. doi: 10.1136/ard-2022-222835. Epub 2022 Sep 13. PMID: 36100351.
• Christiansen SN, Ørnbjerg LM, Rasmussen SH, Loft AG, Askling J, Iannone F, Zavada J, Michelsen B, Nissen M, Onen F, Santos MJ, Pombo-Suarez M, Relas H, Macfarlane GJ, Tomsic M, Codreanu C, Gudbjornsson B, Van der Horst-Bruinsma I, Di Giuseppe D, Glintborg B, Gremese E, Pavelka K, Kristianslund EK, Ciurea A, Akkoc N, Barcelos A, Sánchez-Piedra C, Peltomaa R, Jones GT, Rotar Z, Ionescu R, Grondal G, Van de Sande MGH, Laas K, Østergaard M, Hetland ML.
  European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
  Rheumatology (Oxford). 2022 Aug 30;61(9):3799-3807. doi: 10.1093/rheumatology/keab945. PMID: 34940840.
• Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG, Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML.
  Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
  Arthritis Care Res (Hoboken). 2022 Jul;74(7):1205-1218. doi: 10.1002/acr.24560. Epub 2022 Apr 29. PMID: 33460531.
• Nissen M, Delcoigne B, Di Giuseppe D, Jacobsson L, Hetland ML, Ciurea A, Nekvindova L, Iannone F, Akkoc N, Sokka-Isler T, Fagerli KM, Santos MJ, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, van der Horst-Bruinsma I, Loft AG, Möller B, Mann H, Conti F, Yildirim Cetin G, Relas H, Michelsen B, Avila Ribeiro P, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Askling J, Glintborg B, Lindström U.
  The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
  Rheumatology (Oxford). 2022 Nov 28;61(12):4741-4751. doi: 10.1093/rheumatology/keac174. PMID: 35323903.
• Ørnbjerg LM, Linde L, Georgiadis S, Rasmussen SH, Lindström U, Askling J, Michelsen B, Giuseppe DD, Wallman JK, Pavelka K, Závada J, Nissen MJ, Jones GT, Relas H, Pirilä L, Tomšič M, Rotar Z, Geirsson AJ, Gudbjornsson B, Kristianslund EK, van Sder Horst-Bruinsma I, Loft AG, Laas K, Iannone F, Corrado A, Ciurea A, Santos MJ, Santos H, Codreanu C, Akkoc N, Gunduz OS, Glintborg B, Østergaard M, Hetland ML.
  Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
  Semin Arthritis Rheum. 2022 Oct;56:152081. doi: 10.1016/j.semarthrit.2022.152081. Epub 2022 Aug 10. Erratum in: Semin Arthritis Rheum. 2023 Feb;58:152141. PMID: 35985172.
• Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Lindström U, Pavelka K, Yilmaz N, Favalli EG, Nissen MJ, Michelsen B, Vieira-Sousa E, Jones GT, Ionescu R, Relas H, Sanchez-Piedra C, Tomšič M, Geirsson AJ, van der Horst-Bruinsma I, Askling J, Loft AG, Nekvindova L, Direskeneli H, Iannone F, Ciurea A, Fagerli KM, Santos MJ, Macfarlane GJ, Codreanu C, Eklund K, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Rusman T, Østergaard M, Hetland ML.
  One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
  J Rheumatol. 2023 Aug;50(8):1009-1019. doi: 10.3899/jrheum.220459. Epub 2022 Dec 1. PMID: 36455943.

ATTRA abstrakta na kongresech EULAR

• 2022 POS0567  SELF-PERCEIVED GENERAL HEALTH AT START OF ANTI-TNF THERAPY PREDICTS THERAPEUTIC RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS FROM THE CZECH BIOLOGICS REGISTRY ATTRA,
  J. Zavada, L. Nekvindova on behalf of Collaborators of the ATTRA registry

2021

Články v mezinárodních odborných časopisech

• Nekvindová, Lucie; Vencovský, Jiří; Pavelka, Karel; Horák, Pavel; Křístková, Zlatuše; Závada, Jakub.
  Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry
  Arthritis Research & Therapy ; 2021 Jan 6, volume 23, issue 1
• Thomas, Matthew L.; Shaddick, Gavin; Charlton, Rachel; Cavill, Charlotte; Holland, Richard; Iannone, Florenzo; Lapadula, Giovanni; Lopriore, Simona; Závada, Jakub; Uher, Michal; Pavelka, Karel; Szczuková, Lenka; Sidiropoulos, Prodromos; Flouri, Irini; Drosos, Alexandros; Möller, Burkhard; Nissen, Michael J.; Müller, Rüdiger B.; Scherer, Almut; McHugh, Neil.
  Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.
  Journal of Rheumatology , Jan2021, Vol. 48 Issue 1, p48-57, 10p
• Lindström U, Di Giuseppe D, Delcoigne B, Glintborg B, Möller B, Ciurea A, Pombo-Suarez M, Sanchez-Piedra C, Eklund K, Relas H, Gudbjornsson B, Love TJ, Jones GT, Codreanu C, Ionescu R, Nekvindova L, Závada J, Atas N, Yolbas S, Fagerli KM, Michelsen B, Rotar Ž, Tomšič M, Iannone F, Santos MJ, Avila-Ribeiro P, Ørnbjerg LM, Østergaard M, Jacobsson LT, Askling J, Nissen MJ.
  Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
  Ann Rheum Dis. 2021 Nov;80(11):1410-1418. doi: 10.1136/annrheumdis-2021-220097. Epub 2021 Jun 3. PMID: 34083206; PMCID: PMC8522446.

ATTRA abstrakta na kongresech EULAR

• 2021 OP0105    FEASIBILITY AND USEFULNESS OF MAPPING BIOLOGIC REGISTRIES TO A COMMON DATA MODEL: ILLUSTRATION USING COMORBIDITIES,
  L. Kearsley-Fleet, K. Hyrich, M. Schaefer, D. Huschek, A. Strangfeld, J. Zavada, M. Lagová, D. Courvoisier, C. Tellenbach, K. Lauper, C. Sánchez-Piedra, N. Montero, J. T. Sánchez-Costa, D. Prieto-Alhambra, E. Burn

• 2021 POS0093  HETEROGENEITY IN ADVERSE EVENT ASSESSMENT BETWEEN COUNTRIES PARTICIPATING IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS USING JANUS KINASE INHIBITORS (THE JAK-POT STUDY),
  K. Lauper, D. Mongin, S. A. Bergstra, D. Choquette, C. Codreanu, D. De Cock, L. Dreyer, O. Elkayam, K. Hyrich, F. Iannone, N. Inanc, E. Kristianslund, T. K. Kvien, B. Leeb, G. Lukina, D. Nordström, K. Pavelka, M. Pombo-Suarez, Z. Rotar, M. J. Santos, A. Strangfeld, D. Courvoisier, A. Finckh on behalf of Epidemiology and registry working group

• 2021 POS0596  THE THERAPEUTIC TARGET IS REACHED MORE OFTEN IN RA PATIENTS STARTING TNF INHIBITORS WITH MODERATE ACTIVITY THAN WITH HIGH DISEASE ACTIVITY – AN ANALYSIS FROM THE ATTRA REGISTRY,
  K. Pavelka, L. Nekvindova, J. Zavada

Abstrakta z kongresů ACR

• ABSTRACT NUMBER: 0237 • ACR Convergence 2021 Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA
  Jakub Zavada and Lucie Nekvindova

2020

Články v mezinárodních a českých odborných časopisech

• Zavada, Jakub; Nekvindova, Lucie.
  Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
  ARTHRITIS & RHEUMATOLOGY; OCT 2020; 72,
• Lauper, Kim; Mongin, Denis; Iannone, Florenzo; Kristianslund, Eirik K.; Kvien, Tore K.; Nordström, Dan C.; Pavelka, Karel; Pombo-Suarez, Manuel; Rotar, Ziga; Santos, Maria J.; Codreanu, Catalin; Lukina, Galina; Gale, Sara L.; John, Markus; Luder, Yves; Courvoisier, Delphine S.; Gabay, Cem.
  Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis
  Seminars in Arthritis and Rheumatism Volume: 50 Issue 1 (2020), 50(1):17-24.
• Tužil J, Mlčoch T, Jirčíková J, Závada J, Nekvindová L, Svoboda M, Uher M, Křístková Z, Vencovský J, Pavelka K, Doležal T.
  Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
  Expert Opin Biol Ther. 2020 Feb;20(2):183-192. doi: 10.1080/14712598.2020.1694900.
• Michelsen B, Lindström U, Codreanu C, Ciurea A, Zavada J, Loft AG, Pombo-Suarez M, Onen F, Kvien TK, Rotar Z, Santos MJ, Iannone F, Hokkanen AM, Gudbjornsson B, Askling J, Ionescu R, Nissen MJ, Pavelka K, Sanchez-Piedra C, Akar S, Sexton J, Tomsic M, Santos H, Sebastiani M, Österlund J, Geirsson AJ, Macfarlane G, van der Horst-Bruinsma I, Georgiadis S, Brahe CH, Ørnbjerg LM, Hetland ML, Østergaard M.
  Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
  RMD Open. 2020 Sep;6(3):e001280. doi: 10.1136/rmdopen-2020-001280.
• Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, Santos MJ, Reino JG, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, van der Horst-Bruinsma IE, Macfarlane GJ, Iannone F, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML.
  Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
  Rheumatology (Oxford). 2020 Jul 1;59(7):1640-1650. doi: 10.1093/rheumatology/kez427.
• PAVELKA, Karel — KŘÍSTKOVÁ, Zlatuše — DUŠEK, Ladislav.
  Národní registr biologické a cílené léčby revmatických onemocnění ATTRA – 20leté zkušenosti.
  Česká revmatologie, 2020, roč. 28, č. 3, s. 120-131
• ŠENOLT, Ladislav — SVOBODA, Michal.
  Zkušenost s inhibitory Janusových kináz v reálné praxi z registru ATTRA.
  Farmakoterapeutická revue, 2020, roč. 5, č. 3, s. 221-229. ISSN: 2533-6878.
• Michelsen B, Ørnbjerg LM, Kvien TK, Pavelka K, Nissen MJ, Nordström D, Santos MJ, Koca SS, Askling J, Rotar Z, Gudbjornsson B, Codreanu C, Loft AG, Kristianslund EK, Mann HF, Ciurea A, Eklund KK, Vieira-Sousa E, Yazici A, Jacobsson L, Tomšič M, Löve TJ, Ionescu R, van der Horst-Bruinsma IE, Iannone F, Pombo-Suarez M, Jones GT, Hyldstrup LH, Krogh NS, Hetland ML, Østergaard M.
  Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
  Rheumatology (Oxford). 2020 Sep 1;59(9):2455-2461. doi: 10.1093/rheumatology/kez656. PMID: 31960053.
• Michelsen B, Lindström U, Codreanu C, Ciurea A, Zavada J, Loft AG, Pombo-Suarez M, Onen F, Kvien TK, Rotar Z, Santos MJ, Iannone F, Hokkanen AM, Gudbjornsson B, Askling J, Ionescu R, Nissen MJ, Pavelka K, Sanchez-Piedra C, Akar S, Sexton J, Tomsic M, Santos H, Sebastiani M, Österlund J, Geirsson AJ, Macfarlane G, van der Horst-Bruinsma I, Georgiadis S, Brahe CH, Ørnbjerg LM, Hetland ML, Østergaard M.
  Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
  RMD Open. 2020 Sep;6(3):e001280. doi: 10.1136/rmdopen-2020-001280. PMID: 32950963; PMCID: PMC7539854.
• Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, Santos MJ, Reino JG, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, van der Horst-Bruinsma IE, Macfarlane GJ, Iannone F, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML.
  Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
  Rheumatology (Oxford). 2020 Jul 1;59(7):1640-1650. doi: 10.1093/rheumatology/kez427. PMID: 31665497.

ATTRA abstrakta na kongresech EULAR

• 2020 OP0109    CO-MEDICATION WITH A CONVENTIONAL SYNTHETIC DMARD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH IMPROVED RETENTION OF TNF INHIBITORS: RESULTS FROM THE EUROSPA COLLABORATION,
  M. Nissen, B. Delcoigne, D. DI Giuseppe, L. T. H. Jacobsson, K. Fagerli, A. G. Loft, A. Ciurea, D. Nordström, Z. Rotar, F. Iannone, M. J. Santos, M. Pombo-Suarez, B. Gudbjornsson, H. Mann, N. Akkoc, C. Codreanu, I. Van der Horst-Bruinsma, B. Michelsen, G. Macfarlane, M. L. Hetland, M. Tomsic, B. Moeller, P. Ávila-Ribeiro, C. Sánchez-Piedra, H. Relas, A. J. Geirsson, L. Nekvindova, G. Yildirim Cetin, R. Ionescu, N. Steen Krogh, J. Askling, B. Glintborg, U. Lindström
• 2020 FRI0283    CO-MEDICATION WITH CSDMARD HAS LITTLE EFFECT ON THE RETENTION OF TNF INHIBITORS IN PSORIATIC ARTHRITIS, RESULTS FROM THE EUROSPA COLLABORATION,
  U. Lindström, D. DI Giuseppe, B. Delcoigne, B. Glintborg, B. Moeller, M. Pombo-Suarez, C. Sánchez-Piedra, K. Eklund, H. Relas, B. Gudbjornsson, T. Love, G. T. Jones, A. Ciurea, C. Codreanu, R. Ionescu, L. Nekvindova, J. Zavada, N. Atas, S. Yolbaş, K. Fagerli, B. Michelsen, Z. Rotar, M. Tomsic, F. Iannone, M. J. Santos, P. Ávila-Ribeiro, L. Midtbøll Ørnbjerg, M. Ǿstergaard, L. T. H. Jacobsson, J. Askling, M. Nissen
• 2020 OP0231    COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY),
  K. Lauper, D. Mongin, S. A. Bergstra, D. Choquette, C. Codreanu, D. De Cock, L. Dreyer, O. Elkayam, K. Hyrich, F. Iannone, N. Inanc, E. Kristianslund, T. K. Kvien, B. Leeb, G. Lukina, D. Nordström, K. Pavelka, M. Pombo-Suarez, Z. Rotar, M. J. Santos, A. Strangfeld, D. Courvoisier, A. Finckh
• 2020 AB1233    GENDER DIFFERENCE IN DISEASE SEVERITY AND TREATMENT OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA), AXIAL SPONDYLOARTHRITIS (AXSPA) AND PSORIATIC ARTHRITIS (PSA) STARTING TREATMENT WITH TARGETED THERAPY IN THE CZECH REPUBLIC,
  J. Zavada, L. Nekvindova, K. Pavelka, P. Horak, J. Vencovský on behalf of collaborators of the ATTRA registry
• 2020 OP0285    TOWARDS IMPLEMENTING THE OMOP CDM ACROSS FIVE EUROPEAN BIOLOGIC REGISTRIES,
  E. Burn, L. Kearsley-Fleet, K. Hyrich, M. Schaefer, D. Huschek, A. Strangfeld, J. Zavada, M. Lagová, D. Courvoisier, C. Tellenbach, K. Lauper, C. Sánchez-Piedra, N. Montero, J. T. Sanchez-Costa, D. Prieto-Alhambra

Abstrakta z kongresů ACR

• ABSTRACT NUMBER: 0813 • ACR Convergence 2020 Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
  Karel Pavelka and Zlatuše Křístková
• ABSTRACT NUMBER: 0816 • ACR Convergence 2020 Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
  Jakub Závada and Lucie Nekvindova

2019

Články v mezinárodních odborných časopisech

• K. Chatzidionysiou, G. Lukina, C. Gabay, ML. Hetland, EM. Hauge, K. Pavelka, D. Nordström, H. Canhão, M. Tomsic, Z. Rotar, E. Lie, TK. Kvien, RF. van Vollenhoven, S. Saevarsdottir.
  Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration
  Scandinavian journal of rheumatology (Trykt utg.). 2019, roč. 48, č. 1, s. 17-23. ISSN: 0300-9742; 1502-7732
• Midtbøll Ørnbjerg, Lykke; Heegaard Brahe, Cecilie; Askling, Johan; Ciurea, Adrian; Mann, Herman; Onen, Fatos; Klami Kristianslund, Eirik; Nordström, Dan; Santos, Maria Jose; Codreanu, Catalin; Gómez-Reino, Juan; Rotar, Ziga; Gudbjornsson, Bjorn; Di Giuseppe, Daniela; Nissen, Michael J.; Pavelka, Karel; Birlik, Merih; Kvien, Tore; Kalervo Eklund, Kari; Barcelos, Anabela.
  Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
  Annals of the Rheumatic Diseases, Nov2019, Vol. 78 Issue 11, p1536-1544, 9p
• Tužil J; Mlčoch T; Jirčíková J; Závada J; Nekvindová L; Svoboda M; Uher M; Křístková Z; Vencovský J; Pavelka K; Doležal T,
  Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
  Expert Opinion On Biological Therapy [Expert Opin Biol Ther], ISSN: 1744-7682, 2020 Feb; Vol. 20 (2), pp. 183-192;
• Lauper, Kim; Mongin, Denis; Alpizar-Rodriguez, Deshire; Codreanu, Catalin; Iannone, Florenzo; Kristianslund, Eirik K; Kvien, Tore K; Pavelka, Karel; Pombo-Suarez, Manuel; Santos, Maria J; Gabay, Cem; Finckh, Axel; Courvoisier, Delphine S.
  Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.
  Rheumatology , Dec2019, Vol. 58 Issue 12, p2221-2229
• Cerezo LA, Šumová B, Hulejová H, Štorkánová H, Szczuková L, Tomčík M, Bečvář R, Pavelka K, Vencovský J, Závada J, Šenolt L. S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology 2019; 37(2): 338-339.
• Bubová K, Forejtová Š, Zegzulková K, Gregová M, Hušáková M, Filková M, Hořínková J, Gatterová J, Tomčík M, Szczuková L, Pavelka K, Šenolt L.
  Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort.
  BMJ Open 2019; 9: e024713.
• Mann H, Závada J, Šenolt L, Bubová K, Nekvindová L, Křístková Z, Horák P, Vencovský J, Pavelka K; the ATTRA Registry.
  Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.
  Clinical and Experimental Rheumatology 2019; 37(2): 342-343.
• Šumová B, Cerezo LA, Szczuková L, Nekvindová L, Uher M, Hulejová H, Moravcová R, Grigorian M, Pavelka K, Vencovský J, Šenolt L, Závada J.
  Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.
  Rheumatology International 2019; 39(3): 469-478
• Ørnbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, Kristianslund EK, Nordström D, Santos MJ, Codreanu C, Gómez-Reino J, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Pavelka K, Birlik M, Kvien T, Eklund KK, Barcelos A, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Loft AG, van der Horst-Bruinsma I, Jones G, Iannone F, Hyldstrup L, Krogh NS, Hetland ML, Østergaard M.
  Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
  Ann Rheum Dis. 2019 Nov;78(11):1536-1544. doi: 10.1136/annrheumdis-2019-215427. Epub 2019 Aug 20. PMID: 31431486.

Odborné příspěvky na mezinárodních konferencích

Annual European Congress of Rheumatology (EULAR 2019)
12.–15. 6. 2019 (Madrid, Španělsko)

• Mann, H ; Nekvindova, L; Zavada, J ; Senolt, L ; Horak, P ; Kristkova, Z ; Vencovsky, J ;Pavelka, K.
  The effect of co-medication with methotrexate or other conventional synthetic disease modifying anti-rheumatic drugs on first tumor necrosis inhibitor drug survival in patients with rheumatoid arthritis: data from the Czech ATTRA registry
  Annals of the Rheumatic Diseases 2019, 78. (S2), 720-721.

Odborné příspěvky na českých konferencích

Třeboňské revmatologické dny 2019
9.–11. 1. 2019, Třeboň

• Vencovský J. Xeljanz v léčbě revmatoidní artritidy – zkušenosti z reálné klinické praxe v ČR a ve světě
• Mann H. Terapie psoriatické artritidy sekukinumabem, výsledky z klinických studií i z běžné klinické praxe. Data získaná z registrů vč. ATTRA.
• Mann H. Průřez monoterapií: známé i neznámé
• Šenolt L. Obtížně léčitelný pacient s RA – teorie a realita ve světle podmínek úhrady, současná situace podle registru ATTRA (setkání center BL)

ATTRA abstrakta na kongresech EULAR

• 2019 FRI0453    DOES DISCORDANCE BETWEEN BASELINE PATIENT’S AND EVALUATOR’S GLOBAL ASSESSMENT OF DISEASE ACTIVITY IMPACT RETENTION AND REMISSION RATES OF TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS? DATA FROM THE EUROSPA RESEARCH COLLABORATION,
• Brigitte Michelsen, Lykke Ørnbjerg, Heřman Mann, Joseph Sexton, Michael Nissen, Maria Jose Santos, Dan Nordström, Lennart T.H. Jacobsson, Ziga Rotar, Björn Gudbjornsson, Süleyman Serdar Koca, Catalin Codreanu, Manuel Pombo-Suarez, Irene van der Horst-Bruinsma, Anne Gitte Loft, Karel Pavelka, Eirik Kristianslund, Burkhard Moeller, Elsa Vieira-Sousa, Anna-Mari Hokkanen, Ulf Lindström, Matija Tomsic, Thorvardur Jon Love, Berna Goker, Ruxandra Ionescu, Carlos Sánchez-Piedra, Marleen van de Sande, Gary Macfarlane, Florenzo Iannone, Lise Hyldstrup, Niels Steen Krogh, Mikkel Ǿstergaard, Merete L. Hetland
• 2019 FRI0378    DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? – RESULTS FROM THE EUROSPA RESEARCH COLLABORATION,
• Lykke Ørnbjerg, Cecilie Heegaard Brahe, Anne Gitte Loft, Johan Askling, Adrian Ciurea, Heřman Mann, Servet Akar, Eirik Kristianslund, Dan Nordström, Maria Jose Santos, Catalin Codreanu, Manuel Pombo-Suarez, Ziga Rotar, Björn Gudbjornsson, Daniela DI Giuseppe, Michael Nissen, Karel Pavelka, Soner Senel, Joe Sexton, Kari Eklund, Anabela Barcelos, Ruxandra Ionescu, Carlos Sánchez-Piedra, Matija Tomsic, Arni Jon Geirsson, Irene van der Horst-Bruinsma, Gary Macfarlane, Florenzo Iannone, Brigitte Michelsen, Lise Hyldstrup, Niels Steen Krogh, Merete L. Hetland, Mikkel Ǿstergaard
• 2019 SAT0614   DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS DEPEND ON THE REASON FOR WITHDRAWAL FROM THE PREVIOUS TREATMENT? – RESULTS FROM THE EUROSPA RESEARCH COLLABORATION, Cecilie Heegaard Brahe, Lykke Ørnbjerg, Lennart T.H. Jacobsson, Michael Nissen, Eirik Kristianslund, Heřman Mann, Maria Jose Santos, Manuel Pombo-Suarez, Dan Nordström, Ziga Rotar, Björn Gudbjornsson, Ediz Dalkiliç, Catalin Codreanu, Anne Gitte Loft, Ulf Lindström, Burkhard Moeller, Joe Sexton, Karel Pavelka, Anabela Barcelos, Carlos Sánchez-Piedra, Kari Eklund, Matija Tomsic, Thorvardur Jon Love, İsmail Sari, Ruxandra Ionescu, Marleen van de Sande, Irene van der Horst-Bruinsma, Gareth T. Jones, Florenzo Iannone, Brigitte Michelsen, Lise Hyldstrup, Niels Steen Krogh, Mikkel Ǿstergaard, Merete L. Hetland
• 2019 AB0752    DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE – RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION,
• Cecilie Heegaard Brahe, Lykke Ørnbjerg, Lennart T.H. Jacobsson, Michael Nissen, Eirik Kristianslund, Heřman Mann, Maria Jose Santos, Manuel Pombo-Suarez, Dan Nordström, Ziga Rotar, Björn Gudbjornsson, Fatos Onen, Catalin Codreanu, Ulf Lindström, Burkhard Moeller, Joe Sexton, Karel Pavelka, Anabela Barcelos, Carlos Sánchez-Piedra, Kari Eklund, Matija Tomsic, Thorvardur Jon Love, Gerçek Can, Ruxandra Ionescu, Anne Gitte Loft, Marleen van de Sande, Irene van der Horst-Bruinsma, Gary Macfarlane, Florenzo Iannone, Lise Hyldstrup, Niels Steen Krogh, Mikkel Ǿstergaard, Merete L. Hetland
• 2019 FRI0403    HIGH BASELINE PATIENT’S COMPARED WITH EVALUATOR’S GLOBAL ASSESSMENT IS ASSOCIATED WITH LOWER RETENTION AND REMISSION RATES OF FIRST TNF INHIBITOR IN AXSPA PATIENTS – DATA FROM THE EUROSPA COLLABORATION,
• Brigitte Michelsen, Lykke Ørnbjerg, Anne Gitte Loft, Joseph Sexton, Adrian Ciurea, Heřman Mann, Kari Eklund, Ayten Yazici, Maria Jose Santos, Johan Askling, Ziga Rotar, Björn Gudbjornsson, Manuel Pombo-Suarez, Catalin Codreanu, Irene van der Horst-Bruinsma, Eirik Kristianslund, Michael Nissen, Karel Pavelka, Nina Trokovic, Nevsun Inanc, Elsa Vieira-Sousa, Daniela DI Giuseppe, Matija Tomsic, Arni Jon Geirsson, Ruxandra Ionescu, Marleen van de Sande, Florenzo Iannone, Carlos Sánchez-Piedra, Gareth T. Jones, Lise Hyldstrup, Niels Steen Krogh, Merete L. Hetland, Mikkel Ǿstergaard
• 2019 FRI0404    POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION,
• Brigitte Michelsen, Cecilie Heegaard Brahe, Johan Askling, Catalin Codreanu, Adrian Ciurea, Anne Gitte Loft, Heřman Mann, Manuel Pombo-Suarez, Fatos Onen, Joe Sexton, Ziga Rotar, Maria Jose Santos, Kari Eklund, Björn Gudbjornsson, Florenzo Iannone, Daniela DI Giuseppe, Ruxandra Ionescu, Michael Nissen, Karel Pavelka, Carlos Sánchez-Piedra, Servet Akar, Eirik Kristianslund, Matija Tomsic, Helena Santos, Nina Trokovic, Arni Jon Geirsson, Ennio Giulio Favalli, Irene van der Horst-Bruinsma, Gary Macfarlane, Lise Hyldstrup, Niels Steen Krogh, Mikkel Ǿstergaard, Merete L. Hetland
• 2019 SAT0391   REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE – POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK,
• Brigitte Michelsen, Cecilie Heegaard Brahe, Lennart T.H. Jacobsson, Michael Nissen, Manuel Pombo-Suarez, Heřman Mann, Ziga Rotar, Joe Sexton, Maria Jose Santos, Dan Nordström, Catalin Codreanu, Björn Gudbjornsson, Sema Yilmaz, Florenzo Iannone, Ulf Lindström, Anne Gitte Loft, Burkhard Moeller, Carlos Sánchez-Piedra, Karel Pavelka, Matija Tomsic, Eirik Kristianslund, Helena Santos, Anna-Mari Hokkanen, Ruxandra Ionescu, Thorvardur Jon Love, Yavuz Pehlivan, Marco Sebastiani, Gareth T. Jones, Irene van der Horst-Bruinsma, Lise Hyldstrup, Niels Steen Krogh, Merete L. Hetland, Mikkel Ǿstergaard
• 2019 FRI0107    THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRY,
• Heřman Mann, Lucie Nekvindova, Jakub Zavada, Ladislav Šenolt, Pavel Horak, Zlatuse Kristkova, Jiří Vencovský, Karel Pavelka
• 2019 SAT0625   TREATMENT RESPONSE AND DRUG RETENTION RATES IN 23,956 BIOLOGIC-NAïVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS INITIATING TNFI TREATMENT – ROUTINE CARE DATA FROM 12 REGISTRIES IN THE EUROSPA COLLABORATION,
• Lykke Ørnbjerg, Cecilie Heegaard Brahe, Anne Gitte Loft, Johan Askling, Adrian Ciurea, Heřman Mann, Fatos Onen, Eirik Kristianslund, Dan Nordström, Maria Jose Santos, Catalin Codreanu, Manuel Pombo-Suarez, Ziga Rotar, Björn Gudbjornsson, Daniela DI Giuseppe, Michael Nissen, Karel Pavelka, Merih Birlik, Joe Sexton, Kari Eklund, Anabela Barcelos, Ruxandra Ionescu, Carlos Sánchez-Piedra, Matija Tomsic, Arni Jon Geirsson, Irene van der Horst-Bruinsma, Gareth T. Jones, Florenzo Iannone, Lise Hyldstrup, Niels Steen Krogh, Merete L. Hetland, Mikkel Ǿstergaard

2018

Články v mezinárodních odborných časopisech

• Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.
  Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
  Annals of the Rheumatic Diseases 2018; 77(9):1276-1282.

Články v českých odborných časopisech

• Karel Pavelka, Lucie Nekvindová, Zlata Křístková
  Nové výsledky monoterapie revmatoidní artritidy inhibitorem receptoru IL-6 tocilizumabem
  Acta medicinae. 2018, roč. 6, č. 13, s. 23-27. ISSN: 1805-398X.
• Pavelka K, Nekvindová L, Křístková Z.
  Dlouhodobé výsledky léčby revmatoidní artritidy adalimumabem v národním registru ATTRA.
  Česká revmatologie 2018, 26 (4), 153-161.

Odborné příspěvky na mezinárodních konferencích

Annual European Congress of Rheumatology (EULAR)
13.–16. 6. 2018 (Amsterodam, Nizozemsko)

• Pavelka K, Zavada J, Kristkova Z, Szczukova L.
  Drug survival of adalimumab in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over 10 years in real-world setting of Czech registry ATTRA.
  Annals of the Rheumatic Diseases 2018; 77(Suppl. 2): 605.
• Mann H, Bubová K, Závada J, Forejtová Š, Křístková Z, Szczuková L, Horák P, Vencovský J, Pavelka K, on behalf of ATTRA registry.
  Efficacy of early versus delayed initiation of anti-TNF-alpha treatment in axial spondyloarthritis. Data from the Czech registry ATTRA.
  Annals of the Rheumatic Diseases 2018; 77(Suppl. 2): 1006.
• Zavada J, Nekvindova L, Pavelka K, Vencovsky J on behalf of collaborators of the ATTRA registry.
  The influence of age, gender, employment status, or education on the choice of bio- similar vs. bio-original variant of the same bDMARD in patients with RA or AS starting biological therapy – real life data from the Czech biologics registry ATTRA.
  Annals of the Rheumatic Diseases 2018; 77(Suppl. 2): 520.

ACR/ARHP Annual Meeting
19.–24. 10. 2018 (Chicago, Illinois, USA)

• Mann, HF ; Zavada, J ; Nekvindova, L ; Kristkova, Z  ; Horak, P; Vencovsky, J ; Pavelka, K: Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry. ARTHRITIS & RHEUMATOLOGY 2018, 70 (9) Meeting Abstract: 2591
• Mann, HF ; Zavada, J  ; Nekvindova, L ; Kristkova, Z  ; Horak, P  ; Vencovsky, J ; Pavelka, K: Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry. ARTHRITIS & RHEUMATOLOGY 2018, 70 (9) Meeting Abstract: 2592

Odborné příspěvky na českých konferencích

Zimní revmatologické dny 2018
10.–12. 1. 2018, Plzeň, ČR

• Vencovský J. Benepali – údaje z reálné klinické praxe v zemích EU a stav v ČR
• Pavelka K. Dlouhodobé výsledky s adalimumabem v českém registru ATTRA
• Šedová L. Zlepšování kvality života cílenou antirevmatickou léčbou
• Mann H. Hodnocení klinické účinnosti terapie abataceptem na podkladě stratifikace podle ACPA protilátek

62. výroční sjezd českých a slovenských revmatologů
20.–22. 9. 2018, Praha

• Pavelka Karel, Svoboda M, Křístková Z
  Dlouhodobé výsledky léčby spondyloartritid golimumabem v klinických studiích a reálné praxi
  Česká revmatologie. 2018, roč. 26, č. 3, s. 189. ISSN: 1210-7905; 1805-4463

ATTRA abstrakta na kongresech EULAR

• 2018 THU0317  Creating a european database of psoriatic arthritis patients treated in routine care – first, preliminary results from the eurospa research network collaboration,
  L.M. Ørnbjerg, M. Østergaard, F. Onen, M. Birlik, Z. Rotar, M. Tomsic, B. Gudbjornsson, T.J. Love, M.J. Nissen, A. Ciurea, D. Nordström, N. Trokovic, M.J. Santos, A. Barcelos, E.K. Kristianslund, T. Kvien, C. Codreanu, E.-M. Hauge, J.
• 2018 SAT0291   Creation of a european database of patients with axial spondyloarthritis treated in clinical practice– initial, preliminary findings from the eurospa research network collaboration,
  L.M. Ørnbjerg, M. Østergaard, F. Onen, G. Can, Z. Rotar, M. Tomsic, B. Gudbjornsson, A.J. Geirsson, M.J. Santos, A. Barcelos, D. Nordström, K. Aaltonen, M.J. Nissen, A. Ciurea, E.K. Kristianslund, T. Kvien, C. Codreanu, E.-M. Hauge, L.
• 2018 FRI0122    Drug survival of adalimumab in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over 10 years in real-world setting of czech registry attra,
  K. Pavelka, J. Zavada, Z. Kristkova, L. Szczukova
• 2018 SAT0285   Efficacy of early versus delayed initiation of anti-tnf-alpha treatment in axial spondyloarthritis. data from the czech registry attra,
  H. Mann, K. Bubov, J. Zavada, . Forejtov, Z. Kstkov, L. Szczukov, P. Hork, J. Vencovsky, K. Pavelka
• 2018 THU0651  The influence of age, gender, employment status, or education on the choice of bio-similar vs. bio-original variant of the same bdmard in patients with ra or as starting biological therapy – real life data from the czech biologics registry attra,
  J. Zavada, L. Nekvindova, K. Pavelka, J. Vencovsky

2017

Články v mezinárodních odborných časopisech

• Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordström D, Canhao H, Santos MJ, Tomsic M, Rotar Z, Hernández MV, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven R. Rituximab retreatment in rheumatoid arthritis in a real-life cohort: data from the CERERRA collaboration. Journal of Rheumatology 2017; 44(2): 162–169.
• Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clinical Rheumatology 2017; 36(4): 773–779.
• Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the Rheumatic Diseases 2017 [Epub ahead of print]
• Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases 2017; 76(2): 386-391.
• Závada J, Hánová P, Hurňáková J, Szczuková L, Uher M, Forejtová Š, Klein M, Mann H, Olejárová M, Růžičková O, Šléglová O, Hejduk K, Pavelka K. The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis - a cohort study. Arthritis Research & Therapy 2017; 19: 5.

Odborné příspěvky na mezinárodních konferencích

ACR/ARHP Annual Meeting
3.–8. 11. 2017 (San Diego, California, USA)

• Mann HF, Zavada J, Forejtová Š, Szczukova L, Křístková Z, Pavelka K. Comparative effectiveness of early versus delayed anti-TNF-α treatment in axial spondyloarthritis. Arthritis & Rheumatology 2017; 69(Suppl. 10): Abstract No. 1538
• Forejtová Š, Zavada J, Szczukova L, Jarosova K, Philipp T, Pavelka K. A non-medical switch from originator infliximab to biosimilar CT-P13 in 36 patients with ankylosing spondylitis: 6 – months clinical outcomes from the Czech biologic registry ATTRA. Arthritis & Rheumatology 2017; 69(Suppl. 10): Abstract No. 1549
• Zavada J, Szczukova L, Pavelka K, Vencovsky J. The effect of anti-TNF therapy on work productivity and activity impairment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over one year – real-life data from the Czech biologics registry ATTRA. Arthritis & Rheumatology 2017; 69(Suppl. 10): Abstract No. 992

Annual European Congress of Rheumatology (EULAR)
14.–17. 6. 2017 (Madrid, Španělsko)

• Závada J, Szczuková L, Vencovský J, Horák P, Pavelka K, on behalf of collaborators of the Attra Registry. Comparison of the effect of anti-TNF therapy on work disability between patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over one year – real-life data from the Czech biologics registry ATTRA. Annals of the Rheumatic Diseases 2017; 76(Suppl. 2): 440.
• Závada J, Szczuková L, Vencovský J, Horák P, Pavelka K, on behalf of collaborators of the Attra Registry. The effects of anti-TNF therapy on work productivity and activity impairment in patients with rheumatoid arthritis over one year – real-life data from Czech biologics registry ATTRA. Annals of the Rheumatic Diseases 2017; 76(Suppl. 2): 451.
• Horák P, Skácelová M, Szczuková L, Smržová A, Vencovský J, Závada J, Pavelka K, on behalf of ATTRA registry Czech Republic. Comparison of etanercept in monotherapy and in combination with synthetic DMARDs: data from the ATTRA registry. Annals of the Rheumatic Diseases 2017; 76(Suppl. 2): 1183.

Odborné příspěvky na českých konferencích

Třeboňské revmatologické dny 2017
4.–6. 1. 2017, Třeboň, ČR

• Jarošová K. Léčba infliximabem u dospělých pacientů s juvenilní idiopatickou artritidou
• Šléglová O. Máme se obávat jaterního selhání při anti TNF léčbě?
• Horváth R. Ovlivnění kvality života pacientů s SpA léčených adalimumabem – výsledky dlouhodobého sledování v registru ATTRA

XII. Setkání českých a slovenských dětských revmatologů, revmatologických sester a fyzioterapeutů
11.–13. 5. 2017, Mikulov, ČR

• Němcová D a kol. Biologická léčba JIA – přehled registru ATTRA

XII. Slapské symposium
8.–10. 6. 2017, Měřín, ČR

• Pavelka K. Predikce odpovědi na anti-TNF léčbu: studie GO-MORE a reálná data z registru ATTRA
• Závada J. Vliv anti-TNF terapie na produktivitu práce a pracovní neschopnost u pacientů s RA, SpA a PsA
• Mann H. Může včasné nasazení biologické léčby ovlivnit léčebné výsledky pacientů s AS? (analýza z registru ATTRA)
• Forejtová Š. Výsledky studie – switching z originálního na biosimilární infliximab

ATTRA abstrakta na kongresech EULAR

• 2017 FRI0450    COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES ,
  M.L. Hetland, M. Østergaard, J. Askling, C. Gabay, D. Nordstrom, O. FitzGerald, M. Hernández Miguel, M. Santos, Z. Rotar, H. Mann, F. Iannone, M.J. Nissen, E. Hauge, J. Gomez-Reino, F. Díaz-González, M. Tomsic, K. Pavelka,
• 2017 AB0387    COMPARISON OF ETANERCEPT IN MONOTHERAPY AND COMBINATION WITH SYNTHETIC DMARDS: DATA FROM ATTRA REGISTRY ,
  P. Horák, M. Skácelová, L. Szczuková, A. Smržová, J. Vencovsky, J. Závada, K. Pavelka
• 2017 THU0621  COMPARISON OF THE EFFECT OF ANTI-TNF THERAPY ON WORK DISABILITY BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS OVER ONE YEAR– REAL LIFE DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA ,
  J. Zavada, L. Szczukova, J. Vencovskyy, P. Horák, K. Pavelka
• 2017 THU0650  THE EFFECT OF ANTI-TNF THERAPY ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS OVER ONE YEAR – REAL LIFE DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA ,
  J. Zavada, L. Szczukova, K. Pavelka, P. Horák, J. Vencovsky

Abstrakta z kongresů ACR

• ABSTRACT NUMBER: 992 • 2017 ACR/ARHP Annual Meeting The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment  in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra. 
  Jakub Zavada, Lenka Szczukova, Karel Pavelka and Jiri Vencovsky
• ABSTRACT NUMBER: 1549 • 2017 ACR/ARHP Annual Meeting A Non-Medical Switch from Originator Infliximab to Biosimilar CT-P13 in 36 Patients with Ankylosing Spondylitis:  6 – Months Clinical Outcomes from the Czech Biologic Registry Attra
  Šárka Forejtová, Jakub Zavada, Lenka Szczukova, Katerina Jarosova, Tom Philipp and Karel Pavelka

2016

Články v mezinárodních odborných časopisech

• Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A. Brief Report: Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European registry analysis. Arthritis & Rheumatology 2016; 68(6): 1346–1352.
• Závada J, Uher M, Sisol K, Forejtová S, Jarošová K, Mann H, Vencovský J, Pavelka K. A tailored approach to reduce dose of anti-TNF drugs may be equally effective but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Annals of the Rheumatic Diseases 2016; 75: 96–102.
• Soukup T, Nekvindova J, Dosedel M, Brtkova J, Toms J, Bastecka D, Bradna P, Vlcek J, Pavek P. Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins. International Journal of Immunopathology and Pharmacology 2016; 29(4): 790-795.
• Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordström DC, Canhão H, Tomšič M, van Vollenhoven R, Gabay C. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. Rheumatology (Oxford) 2016; 55(2): 230–236.

Články v českých odborných časopisech

• Pavelka K, Šedová L, Hejduk K, Dušek L. 15 let zkušeností s biologickou léčbou zánětlivých revmatických onemocnění v národním registru ATTRA. Časopis lékařů českých 2016; 155(6): 285–292.
• Pavelka K, Jarošová K, Suchý D, Uher M, Hejduk K. První zkušenosti s biosimilárním infliximabem CT-P13 u nemocných se zánětlivými revmatickými onemocněními v ČR v národním registru ATTRA. Česká revmatologie 2016; (24)1: 15–30.
• Horváth R, Hurňáková J, Janková R, Philipp T, Szczuková L, Hejduk K, Pavelka K. Účinnost první a následné linie léčby adalimumabem u revmatoidní artritidy: analýza dat Českého národního registru ATTRA. Česká revmatologie 2016; 24(3): 78–91.

Odborné příspěvky na mezinárodních konferencích

Annual European Congress of Rheumatology (EULAR)
8.–11. 6. 2016 (Londýn, Anglie)

• Courvoisier DS, Gottenberg JE, Hernadez MV, Iannone F, Lie E, Canhao H, Pavelka K, Hetland M, Turesson C, Mariette X, Coquette D, Finckh A. Trajectories of disease activity in rheumatoid arthritis patients after abatacept initiation and their association with clinical characteristics. Annals of the Rheumatic Diseases 2016; 75(Suppl. 2): 451–452.

ACR/ARHP Annual Meeting
11.–16. 11. 2016 (Washington, USA)

• Courvoisier D, Alpizar Rodriguez D, Gottenberg JE, Iannone F, Lie E, Santos MJ, Pavelka K, Lund Hetland M, Turesson C, Mariette X, Choquette D, Finckh A. Drug retention of biologics in rheumatoid arthritis patients: the role of baseline characteristics and impact of time-varying factors. Arthritis & Rheumatology 2016; 68(Suppl 10). Abstract No. 2527

11th Central European Congress of Rheumatology
8.–10. 12. 2016 (Praha, ČR)

• Forejtová Š, Závada J, Szczuková L, Hejduk K, Vencovský J, Pavelka K. Comparison of the effect of anti-TNF therapy on measures of physical function and health related quality of life in patients with rheumatoid arthritis and ankylosing spondylitis – results from the Czech biologic registry ATTRA. Česká revmatologie 2016; 24(Suppl.): 49 (CECR).

ATTRA abstrakta na kongresech EULAR

• 2016 AB0204    GLUCOCORTICOID-SPARING EFFECTS OF ABATACEPT IN RHEUMATOID ARTHRITIS ARE ASSOCIATED WITH BOTH ABATACEPT EFFECTIVENESS AND SEROPOSITIVITY ,
  J.-E. Gottenberg, D. Courvoisier, M. Hetland, C. Turesson, H. Canhão, M.V. Hernandez, F. Iannone, E. Lie, K. Pavelka, D. Choquette, X. Mariette, A. Finckh
• 2016 FRI0070    TRAJECTORIES OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS AFTER ABATACEPT INITIATION AND THEIR ASSOCIATION WITH CLINICAL CHARACTERISTICS ,
  D.S. Courvoisier, J.-E. Gottenberg, M.V. Hernandez, F. Iannone, E. Lie, H. Canhao, K. Pavelka, M. Hetland, C. Turesson, X. Mariette, D. Choquette, A. Finckh

2015

Články v mezinárodních odborných časopisech

• Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C. The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open 2015; 1(1):e000040.
• Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PL, van de Laar MA, Lie E, Kvien TK, Canhão H, Fonseca JE, Rotar Z, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL; on behalf of the EULAR Study Group for Registers and Observational Drug Studies. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford) 2015 Jun; 54(6): 1074–1079.

Odborné příspěvky na mezinárodních konferencích

Annual European Congress of Rheumatology (EULAR)
10.–13. 6. 2015 (Řím, Itálie)

• Finckh A, Iannone F, Neto D, Hernandez M, Lie E, Canhao H, Pavelka K, Turesson C, Mariette X, Gottenberg JE, Hetland ML. The impact of patient characteristics and past treatment history on the evolution of functional disability in RA patients treated with abatacept. A pan-european analysis of RA registries. Annals of Rheumatic Diseases 2015; 74(Suppl. 2): 1041–1042.

Controversies in Rheumatology and Autoimmunity (CORA) 2015
12.–14. 3. 2015 (Sorrento, Itálie)

• Mann H, Forejtová Š, Jarošová K, Šenolt L, Závada J, Uher M, Hejduk K, Pavelka K. Efficacy of first line biological monotherapy in RA: data from the Czech registry ATTRA.

Odborné příspěvky na českých konferencích

Třeboňské revmatologické dny 2015
7.–9. 1. 2015, Třeboň

• Pavelka K. První zkušenosti s preparátem Remsima v registru ATTRA

ATTRA abstrakta na kongresech EULAR

• 2015 AB0440    THE IMPACT OF PATIENT CHARACTERISTICS AND PAST TREATMENT HISTORY ON THE EVOLUTION OF FUNCTIONAL DISABILITY IN RA PATIENTS TREATED WITH ABATACEPT. A PAN-EUROPEAN ANALYSIS OF RA REGISTRIES ,
  A. Finckh, F. Iannone, D. Neto, M. Hernández, E. Lie, H. Canhão, K. Pavelka, C. Turesson, X. Mariette, J.-E. Gottenberg, M.L. Hetland

2014 a starší

Články v mezinárodních odborných časopisech

• Horák P, Skácelová M, Hejduk K, Smržová A, Pavelka K. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic – data from the ATTRA registry. Clinical Rheumatology 2013; 32: 1451-1458.
• Pavelka K, Fojtíková M, Hejduk K.: Efficacy of the first and subsequent courses of anti-TNF therapy in patients with ankylosing spondylitis – results from the Czech National Register ATTRA. Reumatologia 2012; 50(4): 276-293.
• Pavelka K, Forejtová Š, Štolfa J, Chroust K, Burešová L, Mann H, Vencovský J. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clinical and Experimental Rheumatology 2009; 27(6): 958-963.

Články v českých odborných časopisech

• Pavelka K, Hejduk K, Mann H. Jaké jsou prediktivní faktory odpovědi na léčbu tocilizumabem v běžné klinické praxi? Zkušenosti z Českého národního registru ATTRA. Česká revmatologie 2013; 21(3): 132-139.
• Závada J, Uher M, Hejduk K, Vencovský J, Pavelka K. Zdravím podmíněná kvalita života u pacientů s revmatoidní artritidou v průběhu prvního roku anti-TNF léčby (hodnocení). Česká revmatologie 2013; 21(3): 123-130.
• Horák P, Skácelová M, Hejduk K, Pavelka K. Abatacept a jeho použití v České republice v léčbě RA - údaje z registru ATTRA. Česká revmatologie 2012; 20(4): 163-169.
• Pavelka K, Chroust K, Burešová L. Rituximab v běžné klinické praxi v léčbě aktivní revmatoidní artritidy. Česká revmatologie 2011; 19(3): 112-117.
• Šléglová O, Burešová L, Vencovský J, Pavelka K. Výskyt infekcí při léčbě antagonisty TNF alfa v registru ATTRA. Česká revmatologie 2011,19(2): 86-91.
• Pavelka K, Gatterová J, Vencovský J, Šedová L, Chroust K. Rentgenová progrese revmatoidní artritidy v běžné klinické praxi - Výsledky z českého registru ATTRA. Rheumatologia 2009; 23(1): 7-11.

Odborné příspěvky na mezinárodních konferencích

2014 ACR/ARHP Annual Meeting
14.–19. 11. 2014 (Boston, USA)

• Mann HF, Forejtova S, Jarosova K, Senolt L, Zavada J, Uher M, Hejduk K, Pavelka K. Efficacy of first line biological monotherapy in RA: data from the Czech Registry ATTRA. Arthritis & Rheumatology 2014; 66(Suppl. 10): Abstract No. 2371
• Pavelka K, Zavada J, Fojtikova M, Forejtova S, Hejduk K. The effect of co-medication with conventional synthetic (cs)DMARDs on achieving low disease activity while persisting on adalimumab therapy in patients with ankylosing spondylitis / axial spondylarthritis (AS)– analysis from the Czech biologics registry ATTRA. Arthritis & Rheumatology 2014; 66(Suppl. 10): Abstract No. 2555

Annual European Congress of Rheumatology (EULAR)
11.–14. 6. 2014 (Paříž, Francie)

• Zavada J, Uher M, Sisol K, Forejtova S, Jarosova K, Mann H, Vencovsky J, Pavelka K. A tailored approach to reduce dose of anti-TNF drugs is equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over one year: a matched observational study. Annals of the Rheumatic Diseases 2014; 73(Suppl. 2): 719

Annual European Congress of Rheumatology (EULAR)
12.–15. 6. 2013 (Madrid, Španělsko)

• Pavelka K, Hejduk K, Mann H, et al. Swollen joints – the only predictor of achieving low disease activity in RA with tocilizumab therapy in Czech national registry ATTRA. Annals of the Rheumatic Diseases 2013; 72(Suppl. 3): 884.
• Horak P, Pavelka K, Hejduk K, et al. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic – data from the ATTRA registry. Annals of the Rheumatic Diseases 2013; 72(Suppl. 3): 887.
• Forejtova S, Zavada J, Jarosova K, et al. Effect of first-line anti-TNF therapy on health related quality of life in patients with ankylosing spondylitis – results from the Czech biologics registry ATTRA. Annals of the Rheumatic Diseases 2013; 72(Suppl. 3): 948-949.

Annual European Congress of Rheumatology (EULAR)
6.–9. 6. 2012 (Berlín, Německo)

• Pavelka K, Chroust K, Nemec P. Predictive factors of efficacy of anti-TNF therapy in real practice: experience from the national registry of biological therapy ATTRA. Annals of the Rheumatic Diseases 2012; 71(Suppl. 3): 517.
• Skacelova S, Pavelka K, Chroust K. Early response to infliximab therapy predicts long-term disease activity outcomes in patients with rheumatoid arthritis: results from the Czech national biological therapy registry (ATTRA). Annals of the Rheumatic Diseases 2012; 71(Suppl. 3): 523–524.

7th Central European Congress of Rheumatology
8.–10. 5. 2008 (Praha, ČR)

• Pavelka K. Efficacy of adalimumab in RA in clinical studies and registries results from National registry ATTRA.
• Chroust K. Project ATTRA – electronic vision.
• Pavelka K. Inhibition of radiographic progression with infliximab in clinical studies and in real practice (registries).

Annual European Congress of Rheumatology (EULAR)
13.–16. 6. 2007 (Barcelona, Španělsko)

• Pavelka K, Tegzova D, Pavelkova A, et al: No effect of dose escalation on infliximab in patiens with rheumatoid arthritis with residual activity – Data from national registry. Annals of the Rheumatic Diseases 2007; 66(Suppl. 2): 56.

Annual European Congress of Rheumatology (EULAR)
13.–16. 6. 2006 (Amsterdam, Nizozemsko)

• Tegzova D, Vencovsky J, Svobodnik A, et al. Clinical register of TNFA blocking therapy of Czech rheumatological society project ATTRA: Clinical efficacy and safety. Results of 4-years study Annals of the Rheumatic Diseases 2006; 65(Suppl. 2): 505–506.

Annual European Congress of Rheumatology (EULAR)
9.–12. 6. 2004 (Berlín, Německo)

• Tegzova D, Vencovsky J, Dusek L, Pavelka K. Clinical register of TNF alpha blocking therapy of Czech rheumatological society. Project ATTRA. Results of study: Clinical efficacy and safety. Annals of the Rheumatic Diseases 2004; 63(Suppl. 1): 263.
• Pavelka K, Vencovsky J, Tegzova D, et al. Radiographic progression in RA patiens treated with infliximab data from the Czech National Registry (ATTRA) Annals of the Rheumatic Diseases 2004; 63(Suppl.1): 263.

Odborné příspěvky na českých konferencích

Jáchymovské revmatologické dny
12.–14. 12. 2007, Jáchymov

• Forejtová Š. Účinnost a bezpečnost biologické léčby AS – výsledky z Registru ATTRA. 
• Forejtová Š, Pavelka K, Chroust K. Účinnost a bezpečnost anti-TNF alfa terapie u pacientů s ankylozující spondylitidou v Českém národním registru ATTRA.
• Gatterová J, Pavelka K, Chroust K. Rentgenová progrese revmatoidní artritidy v projektu ATTRA – Enbrel/Case control.
• Chroust K. Elektronický registr ATTRA.
• Pavelka K. Bezpečnost biologické terapie u revmatologických onemocnění – bezpečnostní profil adalimumabu.Pavelka K. Způsob léčby AS ve střední a východní Evropě a kvality života nemocných AS. Výsledky mezinárodní multicentrické studie.
• Šenolt L. Účinnost anti-TNF alfa léčby na extraskeletární projevy ankylozující spondylitidy.
• Šenolt L. Noviny v biologické léčbě spondylartritid.

ATTRA abstrakta na kongresech EULAR

• 2014 FRI0071    EFFECT OF BIOLOGICAL THERAPY ON FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS ,
  L. Sedová, J. Stolfa, M. Urbanova, M. Uher, K. Hejduk
• 2014 AB0749    EFFECT OF BIOLOGICAL THERAPY ON FATIGUE ON PATIENTS WITH PSORIATIC ARTHRITIS ,
  J. Stolfa, L. Sedova, K. Hejduk, M. Uher
• 2014 SAT0366   EFFECT OF FIRST-LINE ANTI-TNF THERAPY ON FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS – RESULTS FROM THE CZECH BIOLOGICS REGISTRY ATTRA ,
  S. Forejtova, K. Jarosova, M. Votavova, M. Uher, K. Hejduk, K. Pavelka
• 2014 THU0168  MONOTHERAPY WITH BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS-DATA FROM THE CZECH REGISTRY ATTRA ,
  H. Mann, Š. Forejtová, K. Jarošová, L. Šenolt, J. Závada, M. Uher, K. Hejduk, K. Pavelka
• 2014 FRI0322    POSITIVITY FOR RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE IS ASSOCIATED WITH A BETTER DRUG RETENTION OF ABATACEPT: DATA FROM A PANEUROPEAN ANALYSIS OF RA REGISTRIES ,
  J.E. Gottenberg, D. Neto, J. Gomez-Reino, F. Iannone, E. Lie, H. Canhão, K. Pavelka, C. Turesson, M. Hetland, X. Mariette, A. Finckh
• 2014 FRI0543    PREGNANCY OUTCOME IN ADULT JUVENILE IDIOPATHIC ARTHRITIS PATIENTS TREATED WITH BIOLOGIC AGENTS ,
  K. Jarosova, K. Hejduk, M. Uher, J. Vencovsky

Abstrakta z kongresů ACR

• ABSTRACT NUMBER: 2555 • 2014 ACR/ARHP Annual Meeting The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra
  Karel Pavelka, Jakub Zavada, Marketa Fojtikova, Sarka Forejtova and Karel Hejduk
• ABSTRACT NUMBER: 2371 • 2014 ACR/ARHP Annual Meeting Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra
  Herman Mann, Sarka Forejtova, Katerina Jarosova, Ladislav Senolt, Jakub Zavada, Michal Uher, Karel Hejduk and Karel Pavelka